FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine
FDA approved Arexvy, the first RSV vaccine approved for use in the U.S. Arexvy is approved for the prevention of lower respiratory tract disease caused by RSV.
www.fda.govHere’s a concise update on the latest RSV vaccine news up to now.
- RSV vaccines in the US have expanded indications over the past few years. The first RSV vaccine (Arexvy) was approved in 2023 for adults 60+, with ongoing follow-on approvals broadening age ranges and populations (e.g., pregnant individuals for infant protection and additional adult indications).[1]
- Pfizer’s Abrysvo gained approvals for adults 18–59 at high risk and remains approved for use in pregnancy at 32–36 weeks to protect newborns for the first several months, with broader discussions about extending indications to other adult age groups.[2][4][8]
- In 2025–2026, WHO prequalification progressed for maternal RSV vaccines, signaling continued global emphasis on protecting newborns through maternal vaccination strategies.[6]
- The landscape includes ongoing safety monitoring and postmarketing commitments, as regulators weigh potential associations with rare adverse events (e.g., preterm birth signals in some trials) and require continued surveillance.[4][1]
Key takeaways for Marseille, or broadly Europe:
- RSV vaccination programs are increasingly targeting high-risk adults and pregnant individuals to protect infants, alongside ongoing maternal vaccine strategies globally. Specific approvals and age indications vary by country; national health authorities determine local recommendations.
- For infants and pregnant people, maternal immunization remains a cornerstone strategy in many regions, with vaccines like Abrysvo used in pregnancy to confer protection to newborns in the first months of life.[4]
Illustrative example:
- If a 32–36 week pregnant person visits a clinic this RSV season, vaccination with a maternal RSV vaccine could reduce RSV hospitalization risk in the newborn during the first six months of life, according to regulatory approvals in several jurisdictions.[8][4]
Would you like a brief summary tailored to France/Marseille, including current national guidance and available vaccines there, with sources? I can gather the latest country-specific recommendations and regulatory status.